Etoposide is regarded as one of the main standard cytotoxic drugs for lung cancer. However,
mutations in Kelch-like ECH-associated protein 1 (Keap1), the main regulator of nuclear …

Non-small cell lung cancer (NSCLC) has a high mortality rate worldwide. Various treatments
strategies have been used against NSCLC including individualized chemotherapies, but …

Lung adenocarcinomas exhibit chemoresistance mostly due to deregulation of nuclear
factor erythroid-derived 2-like 2 (Nrf2). Epigallocatechin gallate (EGCG), was investigated for …

Since multidrug resistance (MDR) is one of the main reasons for failure in cancer treatment,
its suppression may increase the efficacy of cancer therapy. In the present study we …

Research into the evasion of drug resistance and adverse effects is highly significant and
urgent in the clinic. Therefore, accumulating studies have focused on the development of …

Loss-of-function mutations in the nuclear factor erythroid-2 related factor-2 (Nrf2) inhibitor,
Kelch-like-ECH-associated protein (Keap1), result in increased Nrf2 activity in non–small …

Abstract Gemcitabine (2′-deoxy-2′, 2′-difluorocytidine, dFdC) is one of the most effective
chemotherapy drugs commonly used for treatment of various tumors. Despite its significant …

Loss-of-function mutations in the nuclear factor erythroid-2–related factor 2 (Nrf2) inhibitor
Kelch-like ECH-associated protein 1 (Keap1) result in increased Nrf2 activity in non–small …

The nuclear factor erythroid-2-related factor 2 (Nrf2)–Keap1–ARE pathway, a master
regulator of oxidative stress, has emerged as a promising target for cancer therapy …

Keap1/Nrf2 pathway regulates the antioxidant stress response, detoxification response, and
energy metabolism. Previous reports found that aberrant Keap1/Nrf2 pathway activation due …